Impact of positive ZEB1 expression in patients with epithelial ovarian carcinoma as an oncologic outcome‑predicting indicator

  • Authors:
    • Jun Sakata
    • Hiroaki Kajiyama
    • Shiro Suzuki
    • Fumi Utsumi
    • Kaoru Niimi
    • Ryuichiro Sekiya
    • Kiyosumi Shibata
    • Takeshi Senga
    • Fumitaka Kikkawa
  • View Affiliations

  • Published online on: July 24, 2017     https://doi.org/10.3892/ol.2017.6658
  • Pages: 4287-4293
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Several previous studies have revealed that the expression of zinc finger E‑box binding homeobox 1 (ZEB1) in solid malignancies has an important significance on the clinical outcome of patients. However, the association between ZEB1 expression and survival in patients with epithelial ovarian carcinoma (EOC) remains unclear. The objective of the present study was to examine the extent of ZEB1 expression in EOC using immunohistochemical staining and investigate its association with patient outcome. A total of 40 patients with EOC initially treated with cytoreductive surgery and systematic chemotherapy were enrolled. ZEB1 expression was immunohistochemically categorized as negative, weak, moderate and strong according to the size of the staining area, and intensity. Subsequently, the associations between ZEB1 expression and recurrence/progression‑free survival (RFS) rate were examined. The median age of patients in the current study was 54 years old (range, 22‑72 years old). Among these patients, 15 (37.5%) exhibited International Federation of Gynecology and Obstetrics stage I disease, and 10 (25.0%), 13 (32.5%), and 2 (5%) had stage II, III, and IV disease, respectively. No patients with negative expression of ZEB1 experienced recurrence. In addition, ZEB1 expression was identified to be a significant predictor of a poorer RFS rate compared with negative expression (negative vs. weak, moderate and strong, P=0.0126). Furthermore, multivariate analyses revealed that moderate and strong ZEB1 expression levels were significant prognostic indicators of a poorer RFS rate in patients with EOC (hazard ratio, 2.265; 95% confidence interval, 1.072‑8.021; P=0.0349). Confining analysis to patients with the clear‑cell/mucinous histological type, those with moderate/strong ZEB1 expression demonstrated a significantly poorer RFS rate (P=0.0025). Positive ZEB1 expression may be an indicator to predict unfavorable RFS in patients with EOC.
View Figures
View References

Related Articles

Journal Cover

October 2017
Volume 14 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Sakata, J., Kajiyama, H., Suzuki, S., Utsumi, F., Niimi, K., Sekiya, R. ... Kikkawa, F. (2017). Impact of positive ZEB1 expression in patients with epithelial ovarian carcinoma as an oncologic outcome‑predicting indicator. Oncology Letters, 14, 4287-4293. https://doi.org/10.3892/ol.2017.6658
MLA
Sakata, J., Kajiyama, H., Suzuki, S., Utsumi, F., Niimi, K., Sekiya, R., Shibata, K., Senga, T., Kikkawa, F."Impact of positive ZEB1 expression in patients with epithelial ovarian carcinoma as an oncologic outcome‑predicting indicator". Oncology Letters 14.4 (2017): 4287-4293.
Chicago
Sakata, J., Kajiyama, H., Suzuki, S., Utsumi, F., Niimi, K., Sekiya, R., Shibata, K., Senga, T., Kikkawa, F."Impact of positive ZEB1 expression in patients with epithelial ovarian carcinoma as an oncologic outcome‑predicting indicator". Oncology Letters 14, no. 4 (2017): 4287-4293. https://doi.org/10.3892/ol.2017.6658